Welcome to our dedicated page for Merit Med Sys news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Med Sys stock.
Merit Medical Systems Inc. develops, manufactures and distributes proprietary medical devices used in interventional, diagnostic and therapeutic procedures, with product activity concentrated in cardiology, radiology, oncology, critical care and endoscopy. Company news commonly covers operating results, annual guidance, revenue presentation by Foundational and Therapeutic product categories, and portfolio actions involving acquired or divested device lines.
Recurring updates also include commercial launches and distribution arrangements for products such as the Resilience Through-the-Scope Esophageal Stent, ViaVerte basivertebral nerve ablation system, OneMark Detection Imaging System and OneMark Tissue Markers. Governance announcements and healthcare conference participation appear alongside financial and product disclosures.
Merit Medical (NASDAQ: MMSI) announced the US commercial launch of the Resilience Through-the-Scope (TTS) Esophageal Stent on March 16, 2026. The stent is indicated for esophageal fistulas and malignant strictures and features proprietary anti-migration flanges, a single-handed deployment system, and unique sizes 14x50, 17x50, and 20x50 mm to address placement and migration challenges.
Merit Medical (NASDAQ: MMSI) reported fourth-quarter revenue of $393.9M (up 11%) and fiscal 2025 revenue of $1.516B (up 12%). GAAP EPS was $2.13 for 2025; non-GAAP EPS was $3.83 (up 11%). Free cash flow for 2025 was $215.7M (up 16%).
The company provided fiscal 2026 guidance of $1.61B–$1.63B revenue (+6%–8%) and non-GAAP EPS of $4.01–$4.15 (+5%–8%), and reported cash of $446.4M with total debt of $747.5M as of December 31, 2025.
Merit Medical (NASDAQ: MMSI) announced that the Board appointed F. Ann Millner as Chair of the Board effective January 5, 2026, following Fred P. Lampropoulos’ resignation as director and Chair on January 4, 2026. Lampropoulos will provide consulting services through March 31, 2026.
Merit reported preliminary unaudited Q4 2025 revenue of $389 million to $395 million, up approximately 10%–11% year‑over‑year. Preliminary constant currency revenue rose about 8%–10%, with a foreign exchange impact of $(4.4) million. Merit will release full Q4 and FY2025 results and fiscal 2026 guidance after market close on February 24, 2026 and hold a conference call at 4:30 p.m. ET.
Merit Medical (NASDAQ: MMSI) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. Management will present a company overview on Tuesday, January 13, 2026 at 4:30 PM PT / 7:30 PM ET.
Martha G. Aronson, President and CEO, and Raul Parra, CFO, will deliver the presentation. A live audio webcast will be accessible via Merit’s investor relations "Events" page, and presentation materials will be posted to Merit’s investor relations "Investor Events and Presentations" page. A replay will be available on the site for approximately 90 days.
Merit Medical (NASDAQ: MMSI) said CMS has deferred consideration of its Transitional Pass-Through incremental payment application for the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) to the CY 2027 Outpatient Prospective Payment System, making Jan 1, 2027 the earliest possible effective date. Merit has withdrawn the TPT application and will begin full U.S. commercialization immediately. The company reiterated a 2025 U.S. revenue forecast of $2 million to $4 million for WRAPSODY CIE and cited 24-month efficacy results from its WRAPSODY WAVE Trial as a commercial differentiator. The device has FDA PMA (Dec 19, 2024), Health Canada approval (Apr 30, 2025), CE mark, and availability in Brazil.
Merit Medical (NASDAQ: MMSI) reported 24-month randomized AVF arm results from the WAVE trial showing the WRAPSODY Cell-Impermeable Endoprosthesis (CIE) had superior durability versus PTA.
Key results: target lesion primary patency (TLPP) 48.6% vs. 29.8% (p<0.0001) and access circuit primary patency (ACPP) 31.3% vs. 20.6% (p=0.003) at 24 months in 245 randomized hemodialysis patients across 43 centers. The device has US FDA premarket approval (Dec 19, 2024), Health Canada approval (Apr 30, 2025), CE mark, and availability in Brazil.
Merit Medical (NASDAQ: MMSI) reported 24-month efficacy from the non-randomized AVG cohort of the WAVE trial on Nov 3, 2025. The WRAPSODY CIE achieved a 6-month TLPP of 81.4% versus a 60% performance goal (p<0.0001). At 12 and 24 months TLPP was 60.2% and 41.7%, respectively; access circuit primary patency (ACPP) was 36.2% at 12 months and 25.7% at 24 months. The dataset includes 112 AVG patients across 43 centers; WRAPSODY holds FDA PMA (Dec 19, 2024) and Health Canada approval (Apr 30, 2025).
Merit Medical (NASDAQ: MMSI) reported Q3 2025 revenue $384.2M, up 13.0% year-over-year (constant currency +12.5%).
GAAP net income was $27.8M (GAAP EPS $0.46, down 3.0%), while non-GAAP net income was $54.9M (non-GAAP EPS $0.92, up 6.7%).
Gross margin improved to GAAP 48.5% and non-GAAP 53.6%. Free cash flow for the first nine months was $141.6M, up 17.6% YoY. Cash totaled $392.5M with total debt of $747.5M and ~$697M available borrowing capacity as of Sept 30, 2025.
Merit raised its 2025 guidance to $1.502–$1.515B revenue (11%–12% growth) and non-GAAP EPS $3.66–$3.79.
PENTAX Medical announced on October 15, 2025 an asset purchase agreement selling the C2 CryoBalloon™ technology to Merit Medical Systems (NASDAQ: MMSI). The C2 CryoBalloon, part of PENTAX Medical's therapeutic portfolio since 2017, provides controlled cryotherapy for Barrett's Esophagus and related GI disorders.
Under the agreement, Merit will integrate C2 into its Endoscopy portfolio, transfer product manufacturing to its facility in South Jordan, Utah, and hire several PENTAX Medical employees to support continuity. PENTAX Medical said the sale lets it sharpen focus on its core business of flexible reusable endoscopy and deepen clinical partnerships.
Merit Medical (NASDAQ: MMSI) signed a definitive asset purchase agreement to acquire the C2 CryoBalloon device and related technology from Pentax of America, a PENTAX Medical subsidiary, with closing expected in Q4 2025. Total consideration is $22 million ($19 million cash at closing plus up to $3 million contingent).
Merit expects the assets to contribute ~$1 million revenue from a projected Nov 1–Dec 31, 2025 closing, and to add approximately $6–8 million revenue for the twelve months ending Dec 31, 2026. The company said the deal will initially be dilutive to 2025 and 2026 earnings but is projected to be accretive thereafter.